Form 4: Enanta Pharma Grants Chief Legal Officer 90,000 Stock Options

Enanta Pharmaceuticals has granted its Chief Legal Officer, Matthew Paul Kowalsky, 90,000 stock options with an exercise price of $13.66, vesting over four years.

Summary

• Matthew Paul Kowalsky, Chief Legal Officer of Enanta Pharmaceuticals Inc. (ENTA), was granted 90,000 stock options.
• The transaction date for this grant was November 25, 2025.
• Each option has an exercise price of $13.66.
• The options will become exercisable quarterly in substantially equal installments over four years from the grant date, subject to continued employment.
• The expiration date for these stock options is November 25, 2035.
• Following this transaction, Matthew Paul Kowalsky beneficially owns 90,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The filing reports a routine executive compensation event (stock option grant), which is generally a neutral to slightly positive signal as it aligns management incentives with shareholder value over the long term.

Positives

• The grant of stock options aligns the Chief Legal Officer's financial interests with those of the shareholders, incentivizing long-term performance.
• This is a standard component of executive compensation, indicating continued commitment to retaining key management.

Future Outlook

The stock options are subject to a four-year vesting schedule, contingent on the optionholder's continued employment, indicating an expectation of long-term tenure for the Chief Legal Officer.

Industry Context

The granting of stock options to key executives is a common practice in the biotechnology and pharmaceutical industries, serving as a primary tool for long-term incentive compensation and talent retention.

Comparison to Industry Standards

• The structure of this option grant, with a multi-year vesting schedule, is consistent with typical executive compensation packages in the biotech sector, designed to encourage long-term commitment and performance.
• The exercise price being set at the market price on the grant date is standard for incentive stock options, aligning the executive's potential gains directly with future stock price appreciation.

Stakeholder Impact

• Shareholders: The grant aligns the Chief Legal Officer's interests with shareholder value creation, as the options gain value only if the stock price increases.
• Employees: The compensation structure for a key executive may influence overall compensation philosophy and morale within the company.

Next Steps

• The stock options will vest quarterly over the next four years, subject to the Chief Legal Officer's continued employment.

Key Dates

Recommendation

This Form 4 reports a standard executive stock option grant, which is a routine component of compensation and does not provide new material information that would significantly alter an investment recommendation. It reflects ongoing executive incentive alignment rather than a change in company fundamentals or outlook.

Keywords

Enanta Pharmaceuticals, ENTA, Stock Option, Executive Compensation, Insider Transaction, Form 4, Matthew Paul Kowalsky